Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China

November 5, 2019 3:30pm Eastern Daylight Time

NEW HAVEN, Conn. and NANJING, China, ( – Simcere Pharmaceutical Group and Aeromics, Inc. today announce collaboration and exclusive license agreement for AER-271, a clinical-stage anti-edema therapy, being developed for the treatment of stroke and other indications, in Greater China (mainland China, Hong Kong, Macau and Taiwan). According to the agreement, Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China.

Read full press release here.